Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, ...

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean ...

The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments. The newly ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the Commissioner’s National Priority Voucher, shortening standard timelines. STEP ...

U.S. Food and Drug Administration (FDA) approved Wegovy pill from Novo Nordisk. The pill will contain 25 mg of ...

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.